L-leucovorin is named as an intervention in 2 current clinical trials in our Canada, Australia, UK, USA, China, Spain, Poland, Japan, South Korea, Taiwan, Singapore, Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Mexico and Israel registers. 1 is recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AstraZeneca (1). The most-studied condition is Gastric Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer
|
Phase 2 | Recruiting | AstraZeneca | UK, USA, China, Spain, Poland, Canada, Japan, South Korea, Taiwan, Singapore, Australia |
|
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
|
Phase 3 | Active, closed | Children's Oncology Group | Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Canada, Mexico, Australia, Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| Children's Oncology Group | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Canada, Australia, UK, USA, China, Spain, Poland, Japan, South Korea, Taiwan, Singapore, Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Mexico and Israel registers name L-leucovorin as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Canada, 1 with sites in Australia, 1 with sites in UK, 1 with sites in USA, 1 with sites in China, 1 with sites in Spain, 1 with sites in Poland, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Taiwan and 1 with sites in Singapore. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
AstraZeneca (1) and Children's Oncology Group (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how L-leucovorin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how L-leucovorin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists L-leucovorin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.